112236 ⎘
Vectors comprising a targeting moiety; Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source Vectors comprising RGD peptide
ENGINEERED MUSCLE TARGETING COMPOSITIONS
#2ENGINEERED MUSCLE TARGETING COMPOSITIONS
#3ENGINEERED MUSCLE TARGETING COMPOSITIONS
#4Phagemid Vector
#5DETARGETED ADENOVIRUS VARIANTS AND RELATED METHODS
#6ENGINEERED MUSCLE TARGETING COMPOSITIONS
#7Engineered muscle targeting compositions
#8ADENOSOMES
#9Cancer treatment
#10Detargeted adenovirus variants and related methods
#11Phagemid vector
#12METHODS AND COMPOSITIONS RELATED TO ADENOASSOCIATED VIRUS-PHAGE PARTICLES
#13Detargeted adenovirus variants and related methods
#14Mutated structural protein of a parvovirus
#15Multitargeting onocolytic adenovirus, methods of use, and methods of making
#16Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
#17M13 bacteriophage as a chemoaddressable nanoparticle for biological and medical applications
#18Mutated structural protein of a parvovirus
#19Viral Vectors with Improved Properties
#20INFECTIVITY-ENHANCED CONDITIONALLY-REPLICATIVE ADENOVIRUS AND USES THEREOF
#21Methods and compositions related to adenoassociated virus-phage particles
#22MODIFIED PLANT VIRUS PARTICLES AND USES THEREFOR
#23Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
#24AVV Vectors and Methods
#25Methods and compositions related to adenoassociated virus-phage particles
#26MUTATED STRUCTURAL PROTEIN OF A PARVOVIRUS
#27ELECTROSTATIC COATING OF PARTICLES FOR DRUG DELIVERY
#28M13 bacteriophage as a chemoaddressable nanoparticle for biological and medical applications
#29Compositions and methods for retinal transduction and photoreceptor specific transgene expression
#30METHOD FOR INHIBITING OR TREATING A DISEASE ASSOCIATED WITH INTRACELLULAR FORMATION OF PROTEIN FIBRILLAR OR AGGREGATES
#31Pseudotyped retroviral vectors and methods of use thereof
#32METHODS FOR DELIVERY OF NUCLEIC ACIDS
#33Compositions and methods for generating and screening adenoviral libraries
#34Cancer-targeted viral vectors
#35Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
#36METHODS AND COMPOSITIONS RELATED TO ADENOASSOCIATED VIRUS-PHAGE PARTICLES
#37Internally administered therapeutic agents for diseases in central and peripheral nervous system comprising mesenchymal cells as an active ingredient
#38Use of receptor sequences for immobilizing gene vectors on surfaces
#39Viral vectors with improved properties
#40Novel virus vector
#41Peptide-enhanced transfections
#42Virus vectors and methods of making and administering the same
#43Virus vectors and methods of making and administering the same
#44Method of using adenoviral vectors with increased persistence in vivo
#45Methods for delivery of nucleic acids
#46Hpma-polyamine conjugates and uses therefore
#47AAV vectors and methods
#48Cancer - targeted viral vectors
#49Vectors and methods for gene transfer
#50Altering viral tropism
#51Chimeric adenovirus capsid proteins
#52Lipid-comprising drug delivery complexes and methods for their production